Pulmonary arterial hypertension non-human primate model and construction method thereof

A pulmonary arterial hypertension, primate technology, applied in the field of medicine, can solve the problem of difficulty in establishing a non-human primate pulmonary arterial hypertension animal model, etc., and achieve the effect of good biocompatibility

Pending Publication Date: 2022-08-02
上海浦灵生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Monocrotaline has been successfully established animal models of pulmonary arterial hypertension in rodents and small pigs. However, due to the different species of non-human primates, it is difficult to establish non-human primates with monocrotaline injection. Animal model of long-term pulmonary hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pulmonary arterial hypertension non-human primate model and construction method thereof
  • Pulmonary arterial hypertension non-human primate model and construction method thereof
  • Pulmonary arterial hypertension non-human primate model and construction method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0030] The present invention provides a preparation method of degradable embolic particles, the preparation method comprising the following steps:

[0031] 1) After centrifuging the blood, take the supernatant layer, platelet layer and part of the red blood cell layer;

[0032] 2) Centrifuge again and discard part of the supernatant;

[0033] 3) After adding thrombin to the remaining system, inject it into the silicone tube, and let it stand to form a thrombus strip;

[0034] 4) After standing, the thrombus strip is taken out, and degradable embolic particles are obtained after permeable membrane filtration.

[0035] In one embodiment, the blood is selected from venous blood or arterial blood.

[0036] The blood is derived from autologous blood of experimental animals. Autologous blood prevents clotting. In the present invention, the experimental animals are experimental animals obtained in compliance with laws and administrative regulations. The experimental animals are,...

Embodiment 1

[0070] Example 1 Construction of a non-human primate model of pulmonary arterial hypertension using degradable embolic particles

[0071] 1. Mechanism of degradable embolic particles inducing pulmonary hypertension:

[0072] The non-human primate femoral vein was punctured by the Seldinger technique to establish a right heart catheter access, and the degradable biocompatible embolic particles were injected into the right atrium through the right heart catheter, and the main pulmonary artery, branches of the pulmonary artery, peripheral pulmonary arteries and capillaries were reached through blood circulation. The mesh is the first barrier encountered during its circulation. The diameter of the degradable biocompatible embolic particles is larger than the diameter of the peripheral pulmonary artery and capillary network, which leads to pulmonary hypertension by mechanically blocking the branches of the pulmonary artery and inducing autologous thrombosis.

[0073] 2. Inducing ma...

Embodiment 2

[0111] Example 2. Constructing a non-human primate model of pulmonary hypertension by using autologous thrombus

[0112] 1. Mechanism of autologous thrombosis-induced pulmonary hypertension:

[0113] The Seldinger technique is used to puncture the femoral vein to establish a right heart catheter access, and a certain size and length of autologous thromboembolism is injected into the right atrium through the right heart catheter, and then reaches the main pulmonary artery and branches of the pulmonary artery through blood circulation. The first barrier encountered during circulation, whose diameter is larger than the diameter of the peripheral pulmonary artery, can lead to pulmonary hypertension by mechanically occluding larger branches of the pulmonary artery and inducing autologous thrombosis.

[0114] 2. Embolization material: autologous thromboembolism

[0115] Preparation of autologous thrombus: 5 ml of animal autologous whole blood plus 20 ul of thrombin was quickly inje...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine, in particular to a pulmonary arterial hypertension non-human primate model and a construction method thereof.The construction method of the pulmonary arterial hypertension non-human primate model comprises the following steps that a Seldinger technology is used for puncturing femoral veins to establish a right heart catheter channel; the degradable embolism particles or the degradable embolism particle preparation is injected into the right atrium of an experimental animal body through a right heart catheter, the degradable embolism particles block pulmonary artery branches and induce autologous thrombus formation through blood circulation, and therefore the pulmonary arterial hypertension animal model is obtained. Compared with a rodent model or a pig model, the pulmonary arterial hypertension non-human primate model is closer to a disease state under human pulmonary arterial hypertension; the degradable embolism particles used by the model can be degraded and absorbed along with time in the animal body, and the thrombolytic drug can obviously accelerate the process, so that the model can be used for screening the thrombolytic drug, and is suitable for developing thrombolytic drug curative effect evaluation experiment research.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a non-human primate model of pulmonary arterial hypertension and a construction method thereof. Background technique [0002] Pulmonary arterial hypertension (PAH) is a chronic pulmonary circulatory disease characterized by multiple etiologies, complex pathogenesis, progressive increase in pulmonary vascular resistance and eventually irreversible pathological changes. One of the factors is that without effective treatment, some patients will eventually progress to right heart failure and die. [0003] Since the pathogenesis of PAH is not completely clear, the development of relevant animal models has become the main means for people to explore its pathogenesis. At present, the application research of PAH animal models at home and abroad mainly focuses on rodents. However, due to the large genetic differences between rodents and humans, many effective reagents tested in rodent models are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61D7/00A61K49/00
CPCA61D7/00A61K49/0008
Inventor 邱志富刘巍邓继林宋之战
Owner 上海浦灵生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap